Health Industry News 16 October 2025

Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Updated: Sunday, December 14, 2025 (U.S. markets last closed Friday, Dec. 12) Pfizer Inc. (NYSE: PFE) is ending the week in a familiar spot—trading in the mid‑$20s—while investors weigh a high dividend payout against a fast-moving set of catalysts: new

14 December 2025

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (NYSE: PFE) heads into Thursday’s session with its share price hovering around yesterday’s close, as investors digest a flurry of news on cost cuts, obesity drug deals, and a big hedge fund trimming its stake. As of around 6:05

11 December 2025

Company Earnings · Health Industry · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market

UnitedHealth Group (UNH) Stock Today: Price, West Virginia Opioid Lawsuit, Guidance Raise and 2026 Forecasts

Date: December 9, 2025Ticker: UnitedHealth Group Incorporated (NYSE: UNH) UnitedHealth Group stock is trading roughly flat on Tuesday, even as investors digest fresh legal headlines, a recent earnings guidance upgrade, and a broad range of Wall Street forecasts that still

9 December 2025

Financial Forecasts · Health Industry · Investment Analysis · Legal News · Stock Market

Hims & Hers Health (HIMS) Stock Jumps on Policy Tailwinds and Buyback Momentum — November 24, 2025

Hims & Hers Health Inc. (NYSE: HIMS) ended Monday’s U.S. session sharply higher, extending a volatile but strongly positive year for the fast‑growing telehealth platform. Below is a news-style, SEO-optimized breakdown of Hims & Hers Health (HIMS) stock today (24.11.2025),

24 November 2025

Company Analysis · Financial News · Health Industry · Investment Strategies · NYSE:HIMS · Stock Market

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer stock (NYSE: PFE) spent most of Thursday in the red as investors weighed a near‑7% dividend yield against fresh legal headlines, new R&D wins and ongoing questions about the company’s post‑COVID growth story. As of late U.S. trading on

20 November 2025

Dividends · Health Industry · Legal News · NYSE:PFE · Pharmaceuticals · Stock Market

GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK plc (NYSE: GSK; LSE: GSK) generated several headlines today: a fresh research tie‑up in tuberculosis drug discovery, confirmation of ongoing share repurchases via a new U.K. regulatory filing, and a U.S.‑listed share price that pushed to a new 12‑month

11 November 2025

Collaborations · Company News · Health Industry · Pharmaceuticals · Stock Market

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Company Background & Significance Founded in 1849, Pfizer Inc. has grown into a pillar of the pharmaceutical industry, known for landmark drugs and vaccines. From breakthrough treatments like Lipitor (cholesterol) and Viagra (ED), to its 2020 partnership with BioNTech delivering

2 November 2025

Health Industry · Investing · Market News · NYSE:PFE · Pharmaceuticals · Stocks

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Market Snapshot (pre-market Nov 3) As of Oct. 31 close, Eli Lilly (NYSE:LLY) was around $862–864 (with after-hours ~864) stockanalysis.com marketbeat.com. That’s up ~9–10% from early October nasdaq.com. Trading volumes have been heavy, and LLY remains near its 52-week high

2 November 2025

Eli Lilly · Health Industry · NYSE:LLY · Pharmaceuticals · Pre-Market · Stock Forecast

CSL’s Vaccine Shock: Stock Plunges to 7-Year Low Amid Shareholder Revolt

Vaccine Slump Triggers Profit Downgrade and 7-Year Share Low CSL – Australia’s fourth-largest public company – stunned the market by cutting its profit outlook and delaying a major spinoff due to a steep and unexpected decline in flu vaccinations in the United

28 October 2025

Business News · Health Industry · NYSE:CSLLY · Shareholder Activism · Stock Market · Vaccines

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

PFE Stock Price and Recent Performance Pfizer’s stock has endured a rough 2025, trading in the low-to-mid $20s for much of the year and touching multi-year lows. By late September, PFE was around $23.60 – down ~9% year-to-date and ~18%

27 October 2025

Business News · Health Industry · Investing · NYSE:PFE · Pharmaceuticals · Stock Market

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Recent Market Moves Kenvue’s stock (NYSE: KVUE) has been volatile. On Oct 16, 2025 it closed around $15.46, marking a fresh 52-week low investing.com. Over the prior week the shares had slid ~13%, partly driven by jitters over UK talc

16 October 2025

Health Industry · Investment News · Market Analysis · NYSE:KVUE · Pharmaceutical Companies · Stock Market

Health Industry News 16 October 2025 - 14 December 2025